Novel risk models for early detection and screening of ovarian cancer

Oncotarget

Volumn 8, Issue 1, 2017, Pages 785-797

  Russell, Matthew R ^a   D'Amato, Alfonsina ^a   Graham, Ciaren ^b   Crosbie, Emma J ^c   Gentry Maharaj, Aleksandra ^d   Ryan, Andy ^d   Kalsi, Jatinderpal K ^d   Fourkala, Evangelia Ourania ^d   Dive, Caroline ^e   Walker, Michael ^a   Whetton, Anthony D ^a   Menon, Usha ^d   Jacobs, Ian ^a,d,f   Graham, Robert L J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Early detection; Logit; Ovarian cancer; Risk estimation; UKCTOCS

Indexed keywords

C REACTIVE PROTEIN; CA 125 ANTIGEN; FATTY ACID BINDING PROTEIN; FIBRONECTIN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; OVARY CANCER; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ALGORITHM; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; MASS SCREENING; OVARY TUMOR; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RISK; STATISTICAL MODEL;

ALGORITHMS; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; EPIDEMIOLOGIC FACTORS; FEMALE; HUMANS; MASS SCREENING; MODELS, STATISTICAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK; ROC CURVE;

EID: 85009758047     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13648     Document Type: Article

References (40)

1. Kurman RJ, Shih I-M. The Origin and Pathogenesis of Epithelial Ovarian Cancer-a Proposed Unifying Theory. Am J Surg Pathol. 2010; 34:433-443.
2. Shih I-M, Kurman RJ. Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis. Am J Pathol. 2004; 164:1511-1518.
3. Hüttenhain R, Soste M, Selevsek N, Röst H, Sethi A, Carapito C, Farrah T, Deutsch EW, Kusebauch U, Moritz RL, Niméus-Malmström E, Rinner O, Aebersold R. Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics. Sci Transl Med. 2012; 4:142ra194.
4. Nolen BM, Lokshin AE. Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol. 2011; 8:55-71.
5. CRUK. Ovarian Cancer Survival statistics.
6. Bristow RE, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET, Munroe DG. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013; 128:252-259.
7. Cramer DW, Bast RC, Jr., Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res. 2011; 4:365-374.
8. Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, Urban N, McIntosh MW. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol. 2013; 31:387-392.
9. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10:327-340.
10. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast Jr RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009; 112:40-46.
11. Skates SJ. OCS: Development of the Risk of Ovarian Cancer Algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer. 2012; 22:S24-S26.
12. Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Rep. 1989; 4:1-12.
13. Zhu CS, Pinsky PF, Cramer DW, RansohoffDF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, et al. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. Cancer Prev Res. 2011; 4:375-383.
14. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, Mosgaard BJ, Nordin A, Rosen B, Engholm G, GjerstorffML, Hatcher J, Johannesen TB, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol. 2012; 127:75-82.
15. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, et al. Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study. BMJ. 2008; 337.
16. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, et al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015.
17. Russell MR, Walker MJ, Williamson AJK, Gentry-Maharaj A, Ryan A, Kalsi J, Skates S, D'Amato A, Dive C, Pernemalm M, Humphryes PC, Fourkala E-O, Whetton AD, et al. Protein Z: A putative novel biomarker for early detection of ovarian cancer. Int J Cancer. 2016; 138:2984-2992.
18. Nolen BM, Lokshin AE. Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol. 2012; 8:55-71.
19. Hefler-Frischmuth K, Hefler LA, Heinze G, Paseka V, Grimm C, Tempfer CB. Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol. 2009; 147:65-68.
20. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers. Clin Cancer Res. 2005; 11:3686-3696.
21. Gillet J-P, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. Clin Cancer Res. 2012; 18:3197-3206.
22. O'Connor JPB, Rose CJ, Jackson A, Watson Y, Cheung S, Maders F, Whitcher BJ, Roberts C, Buonaccorsi GA, Thompson G, Clamp AR, Jayson GC, Parker GJM. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer. 2011; 105:139-145.
23. Bristow RE, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET, Munroe DG. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013; 128:252-259.
24. Chudecka-Glaz AM. ROMA, an algorithm for ovarian cancer. Clinica Chimica Acta. 2015; 440:143-151.
25. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111:1805-1812.
26. Pankov R, Yamada KM. Fibronectin at a glance. Journal of Cell Science. 2002; 115:3861-3863.
27. Fernandez-Garcia B, Eiro N, Marin L, Gonzalez-Reyes S, Gonzalez LO, Lamelas ML, Vizoso FJ. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology. 2014; 64:512-522.
28. Frankie FE, Von Georgi R, Zygmunt M, Münstedt K. Association between Fibronectin Expression and Prognosis in Ovarian Carcinoma. Anticancer Res. 2003; 23:4261-4267.
29. Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int. 2014; 38:85-91.
30. Broze GJ. Protein Z-dependent regulation of coagulation. J Thromb Haemost. 2001; 86:8-13.
31. Wojtukiewicz MZ, Sierko E, Kisiel W. The role of hemostatic system inhibitors in malignancy. J Thromb Haemost. 2007; 33:621-642.
32. Galar M, Piszcz J, Bolkun L, Szumowska A, Kloczko J. Protein Z Concentrations in Patients With Acute Leukemia. Clin Appl Thromb Hemost. 2012; 18:542-545.
33. Sierko E, Wojtukiewicz MZ, Zimnoch L, Tokajuk P, Ostrowska-Cichocka K, Kisiel W. Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer. Ann Hematol. 2014; 93:779-784.
34. Sierko E, Wojtukiewicz MZ, Zimnoch L, Tokajuk P, Kisiel W. Protein Z is present in human breast cancer tissue. Int J Hematol. 2011; 93:681-683.
35. Sierko E, Wojtukiewicz MZ, Zimnoch L, Tokajuk P, Ostrowska-Cichocka K, Kisiel W. Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: Implications for coagulation regulation on tumor cells. Thromb Res. 2012; 129:E112-E118.
36. Shih IM, Kurman RJ. Ovarian tumorigenesis-A proposed model based on morphological and molecular genetic analysis. American Journal of Pathology. 2004; 164:1511-1518.
37. Wu R, Baker SJ, Hu TC, Norman KM, Fearon ER, Cho KR. Type I to Type II Ovarian Carcinoma Progression: Mutant Trp53 or Pik3ca Confers a More Aggressive Tumor Phenotype in a Mouse Model of Ovarian Cancer. Am J Pathol. 2013; 182:1391-1399.
38. Kurman RJ, Shih I-M. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016; 186:733-747.
39. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003; 21:206s-210s.
40. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Muller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77.